Defining precursor conditions in multiple myeloma & strategies to better predict risk of progression

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the importance of accurately defining precursor conditions, including monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Dr Ghobrial also explains the need to improve strategies and use novel biomarkers to better predict which individuals with MGUS are at risk of progressing to myeloma versus those who are not at risk. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.